1 / 39

SYSTEMIC LUPUS ERYTHEMATOSUS

SYSTEMIC LUPUS ERYTHEMATOSUS. Violeta Rus, MD, PhD Associate Professor of Medicine Rheumatology and Clinical Immunology. Systemic Lupus Erythematosus. Epidemiology Pathogenesis Clinical Features Treatment. SLE: prototypical systemic autoimmune disease. EPIDEMIOLOGY.

meadow
Download Presentation

SYSTEMIC LUPUS ERYTHEMATOSUS

An Image/Link below is provided (as is) to download presentation Download Policy: Content on the Website is provided to you AS IS for your information and personal use and may not be sold / licensed / shared on other websites without getting consent from its author. Content is provided to you AS IS for your information and personal use only. Download presentation by click this link. While downloading, if for some reason you are not able to download a presentation, the publisher may have deleted the file from their server. During download, if you can't get a presentation, the file might be deleted by the publisher.

E N D

Presentation Transcript

  1. SYSTEMIC LUPUS ERYTHEMATOSUS Violeta Rus, MD, PhD Associate Professor of Medicine Rheumatology and Clinical Immunology

  2. Systemic Lupus Erythematosus Epidemiology Pathogenesis Clinical Features Treatment

  3. SLE: prototypical systemic autoimmune disease

  4. EPIDEMIOLOGY • One of the most common autoimmunediseases (1:2500). 2. Female:male ratio is 9:1 3. Mean age at diagnosis is 30; peak age is between 15 and 45 • African-Americanand Hispanic womenhave a 3-5 fold greater incidence compared to whites (frequency 1:245) • Incidence of SLE has tripled in the past four decades

  5. EPIDEMIOLOGY

  6. PATHOGENESIS Etiology unknown: • Genetic predisposition • Environmental factors • Abnormalities of the immune system

  7. GENETIC FACTORS • Genetic predisposition: • Familial clustering • Concordance rate in monozygotic twins (24%) higher than in dizygotic twins (1-3%) • Genome studies • Complex pattern: many genes (50) may be contributing to SLE.

  8. GENETIC FACTORS Chromosome location Candidate Odds GenesRatio • 1q23 FcγRII ~4 • 1q25-31 ? • 1q41-q44 PARP • 2q35-37 PDCD1 ~2.6 • 4p16 ? • 6p11-p21 MHC class II:DR3 ~3 MHC class III: TNFα C2, C4 ~4.5 • 12q24 ? • 16q12-q13 OAZ

  9. ENVIRONMENTAL FACTORS • DRUGS • hydralazine, procainamide, D-penicillamine • reversible with stopping of medication • associated with anti-histone autoantibody. • Viral illness: Epstein-Barr virus • UV light

  10. PATHOGENESIS

  11. Phases in the Development of Lupus Arbuckle, M. R. et al. N Engl J Med 2003;349:1526-1533

  12. Malar Rash Discoid rash Photosensitivity Oral ulcers Arthritis Serositis Renal disorder Neurologic disorder Hematologic disorder Classification criteriaof SLE(1997 ACR revised criteria) • 10. Immunologic disorder • - anti-dsDNA OR • - anti- Sm OR • - antiphospholipid antibody: • positive IgG or IgM ACL Abs • lupus anticoagulant OR • false positive VDRL • 11. Abnormal titer of ANA at any • point in time in absence of drugs For diagnosis: any 4 of 11 criteria

  13. 1. MALAR (butterfly) RASH CLINICAL FEATURES Facial eruption in a patient with systemic lupus erythematosus.

  14. 2. DISCOID LUPUS • coin and round-shaped scalyplaques • hyperpigmentation at the periphery • central atrophy and depigmentation

  15. 4.Oral ulcers

  16. ALOPECIA Lupus hair: short, friable hair in frontal area Diffuse hair loss is most common in lupus, although patchy baldness can appear. Hair regrows slowly when the disease becomes inactive.

  17. 5. SLE -Arthritis transitory arthritis; reversible hand deformities

  18. Major Organ Involvement in SLE

  19. Kidney involvement- glomerulonephritis Brain involvement-stroke Heart involvement- pericarditis

  20. Neonatal lupus- anti-Ro (SSA) • Typical skin rash with predilection for the periorbital area • transient • Echocardiogram of congenital heart block • Permanent: requires pace-maker

  21. Diagnostic tools for SLE Laboratory tests: Tests for autoantibodies: • Antinuclear antibody test (ANA) –major serological feature of lupus • Other autoantibody tests (anti-dsDNA, anti-Sm, anti-RNP, anti-Ro [SSA], anti-La [SSB]) • Anticardiolipin antibody Tests for disease activity: • Complement levels (C3,C4), anti-dsDNA Routine labs to monitor “silent involvement”: • Complete blood count • Erythrocyte sedimentation rate (ESR) • Urinalysis • Blood chemistries Kidney biopsy Skin biopsy

  22. ANA Homogenous pattern Specificity: histone Disease association SLE, Drug-Induced Lupus Peripheral (ring) pattern Specificity: dsDNA Disease association: SLE Speckled pattern Specificity: Sm, Ro, La Disease association SLE, neonatal lupus Sjogren sdr

  23. ANA– DISEASE SUBSETS ASSOCIATIONS Antibody to % Disease association

  24. ANA

  25. ANA Frequency in normal population: • 3.3% at titer of 1:320 and 31.7% at titer of 1:40 • Increases with age:10-37% of elderly >70 y/o • Higher in healthy first-degree relatives of patients with autoimmune diseases

  26. ANA • Sensitivity: 98% (2% false negative results) (ability of a test to detect pts who have the disease) • Specificity:86% (significant # of false positives) (ability of a test to detect pts who do not have the disease) • Positive Predictive Value 11% (performs poorly as a screening test) (probability that a positive test correctly identifies an individual who actually has the disease)

  27. Accumulation of Systemic Lupus Erythematosus Autoantibodies

  28. Disease progression • Variable (from clinically ‘silent’ to rapidly progressive) and unpredictable • Flares and remissions • Survival has improved over the past decades: from <50% to >90% five-year survival 20 year survival is 70% • Mortality: 3-5 times greater than general population • Causes of death: • Active disease: nephritis, vasculitis, organ failure • Infections (treatment-related immunosuppressive therapy) • Cardiovascular: accelerated atherosclerosis (women aged 35–44 with SLE have 50-fold increased risk of MI) • Risk of death increased by: race, low socio-economic status, cardiovascular risk factors (smoking, diabetes, elevated cholesterol/lipids)

  29. Clinical Forms Of Severe Lupus

  30. PROGNOSIS • Variable • Factors affecting prognosis: • Demographic and social • Genetic and immunological • Histopathological • Treatment strategy

  31. TREATMENT OF SLE • Three drugs have FDA approval for SLE: • ASA (1940) • Cortisone (1950) • Antimalarials (1956) • From 1960s : Azathioprine, Methotrexate, cyclophosphamide, Cellcept • 2011: first FDA approval for new drug for lupus

  32. TREATMENT Mild Disease

  33. UV light Protection Both UVA and UVB induce lesions: • Sun-protecting clothing • Sunblock SPF >30 (applies to UVB only) • UVA protection: Zn oxide; Ti dioxide; Avobenzone • UV light-blocking films on home and auto windows • Camouflage cosmetics (Dermablend, Covermark) • Avoid photosensitizing drugs (ex: HCTZ)

  34. Antimalarials • Hydroxychloroquine (Plaquenil) • HQ: Start at 400mg/d; maintenance 200mg/d • Smoking decreases efficacy of antimalarials • Adverse effects: Retinopathy • Risk minimal at < 6mg/kg HQ • Baseline (within first mo) and biannual eye exam

  35. TREATMENTSevere Disease Corticosteroids High dose (i.e. prednisone 1 mg/kg/day  or 1g IV methylprednisolone)  Immunosuppressives Azathioprine (Imuran)      Cyclophophamide (Cytoxan)  Methotrexate   Mycophenylate mofetil (Cellcept) 

  36. TREATMENT- Severe Disease Cyclophosphamide: IV equally effective but less toxic than PO (by mouth) • Adverse effects: - bone marrow suppression - infections (herpes zoster) - hemorrhagic cystitis - persistent amenorrhea: risk depends on patient’s age and cumulative dose • Short course: 0% <25 y/o; 25% />31 • Longer course: 17%<25 y/o 100%/>31 Mycophenolate mofetil (Cellcept): diarrhea, myelotoxicity

  37. Benlysta (Belimumab) • First FDA-approved drug for SLE in 50 years • Targets a growth factor for B cells called BLYSS (BAFF) • Monthly IV infusion • Two large trials: 865 patients and 819 patients - reduction in disease activity: 14% vs 9% with placebo - reduction in flare rate - reduction in prednisone dose However… • Magnitude of the benefit: modest • Not indicated for severe cases; efficacy in AA unknown • Costly

  38. Treatment of SLE: Into the 21st Century BLyS inhibitors Proteasome inhibitors pDC Anti-B cell antibodies sBLyS mBLyS BR3 IFN IFN blockade TLR inhibitors cytokines DC B TLR9 TLR inhibitors B7.1/2 B7.1/2 TLR2 TLR4 TLR6 TLR7 TLR8 IFN blockade CTLA4-Ig Abatacept CD28 CD40 IL-2, 4 IL-10 TNF IFN IL-12p40 IFN T CXCL13 CXCR4 IP-10 S1P CD40L pDC TNF blockade MØ TNF IL-1 IL-6 Cytokine inhibitors IFN- IL-12 IL-23 TNF Lymphocyte signaling inhibitors Chemokine - Lymphocyte trafficking modulators IL-6 blockade PC

  39. Future therapies in SLE Drug Target Epratuzumab CD20 LY 2127399 BLyS B cell therapies Atacicept BLyS, April A -623 BLyS Orencia CD80, CD86Costimulation Lupuzor T Lymphocytes Laquinimod T Lymphocytes T cell therapies MEDI- 545 Interferon- alpha Rontalizumab Interferon- alpha IFNalpha- Kinoid Interferon- alpha Anti-Cytokine therapy

More Related